A first-of-its kind antibody treatment may slow the progression of movement problems in some people with Parkinson's disease (PD), early clinical trial data suggest.
Current treatments for PD only ease its symptoms; they don't address its underlying causes in the brain. Now, the new antibody, called prasinezumab, has shown promise in treating one cause of the disease and thus in slowing down its movement symptoms, such as tremors and stiffness.
